Use of mutation profiles to refine the classification of endometrial carcinomas

Journal of Pathology

Volumn 228, Issue 1, 2012, Pages 20-30

  McConechy, Melissa K ^a   Ding, Jiarui ^b,c   Cheang, Maggie C U ^b   Wiegand, Kimberly C ^a   Senz, Janine ^a   Tone, Alicia A ^a   Yang, Winnie ^a   Prentice, Leah M ^a   Tse, Kane ^b   Zeng, Thomas ^b   McDonald, Helen ^b   Schmidt, Amy P ^d   Mutch, David G ^d   McAlpine, Jessica N ^c   Hirst, Martin ^b,c   Shah, Sohrab P ^b,c   Lee, Cheng Han ^c   Goodfellow, Paul J ^d   Gilks, C Blake ^a,c   Huntsman, David G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d USA   (United States)

Author keywords

carcinosarcoma; classification; endometrial carcinoma; endometrioid; mutation profiles; serous; uterine

Indexed keywords

ARID1A GENE; B RAF KINASE GENE; CANCER CLASSIFICATION; CANCER GRADING; CARCINOGENESIS; CARCINOSARCOMA; CTNNB1 GENE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PIK3CA GENE; PPP2R1A GENE; PPP2R5C GENE; PRIORITY JOURNAL; REVIEW; TP53 GENE; TUMOR GENE;

CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 84864764430     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4056     Document Type: Review

References (56)

1. Evans T, Sany O, Pearmain P, et al., Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer 2011; 104: 1505-1510.
2. Bray F, Dos Santos Silva I, Moller H, et al., Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 14: 1132-1142.
3. Bokhman JV,. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
4. Amant F, Moerman P, Neven P, et al., Endometrial cancer. Lancet 2005; 366: 491-505.
5. Clarke BA, Gilks CB,. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 2010; 63: 410-415.
6. Tavassoli FA, Devilee P,. Pathology and Genetics Tumours of the Breast and Female Genital Organs, IARC WHO Classification of Tumours, IARC WHO Classification of Tumours, No 4. 3rd ed. WHO Press: Geneva, Switzerland 2003; 217-257.
7. Prat J,. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662.
8. Samarnthai N, Hall K, Yeh IT,. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010; 2010: 162363.
9. Catasus L, Gallardo A, Prat J,. Molecular genetics of endometrial carcinoma. Diagnostic Histopathology 2009; 15: 554-563.
10. Alkushi A, Kobel M, Kalloger SE, et al., High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010; 29: 343-350.
11. Hamilton CA, Cheung MK, Osann K, et al., Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94: 642-646.
12. Soslow RA,. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol 2010; 27: 261-273.
13. Sidhu D, Duggan M, Clement P, et al., Interobserver agreement on high-grade endometrial carcinoma and correlation with ER, p53 and p16 expression. Mod Pathol 2012; 25: 296A-297A.
14. Gilks CB, Oliva E, Soslow R,. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. 100th Annual Meeting of the United States and Canadian Academy of Pathology. Lab Invest 2011; 91 (Suppl 1): 248A.
15. Oda K, Stokoe D, Taketani Y, et al., High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65: 10669-10673.
16. Konopka B, Paszko Z, Janiec-Jankowska A, et al., Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett 2002; 178: 43-51.
17. Velasco A, Bussaglia E, Pallares J, et al., PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 2006; 37: 1465-1472.
18. Schlosshauer PW, Pirog EC, Levine RL, et al., Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Modern Pathol 2000; 13: 1066-1071.
19. Okuda T, Sekizawa A, Purwosunu Y, et al., Genetics of endometrial cancers. Obstet Gynecol Int 2010; 2010: 984013.
20. O'Hara AJ, Bell DW,. The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012; 2: 33-47.
21. Pollock PM, Gartside MG, Dejeza LC, et al., Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26: 7158-7162.
22. Goodfellow PJ, Buttin BM, Herzog TJ, et al., Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003; 100: 5908-5913.
23. Urick ME, Rudd ML, Godwin AK, et al., PIK3R1 (p85{;alpha}) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011; 71: 4061-4067.
24. Cheung LW, Hennessy BT, Li J, et al., High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011; 1: 170-185.
25. McConechy MK, Anglesio MS, Kalloger SE, et al., Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011; 223: 567-573.
26. Shih IeM, Panuganti PK, Kuo KT, et al., Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011; 178: 1442-1447.
27. Abeln ECA, Smit VTHBM, Wessels JW, et al., Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumours. J Pathol 1997; 183: 424-431.
28. Voss MA, Ganesan R, Ludeman L, et al., Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol 2012; 124: 15-20.
29. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
30. Morin RD, Mendez-Lago M, Mungall AJ, et al., Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
31. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
32. Ding J, Bashashati A, Roth A, et al., Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 2012; 28: 167-175.
33. Forbes SA, Bindal N, Bamford S, et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
34. Guan B, Mao TL, Panuganti PK, et al., Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011; 35: 625-632.
35. Tashiro H, Blazes MS, Wu R, et al., Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935-3940.
36. Sun H, Enomoto T, Fujita M, et al., Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001; 115: 32-38.
37. Darvishian F, Hummer AJ, Thaler HT, et al., Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004; 28: 1568-1578.
38. D'Angelo E, Prat J,. Pathology of mixed Müllerian tumours. Best Pract Res Clin Obstet Gynaecol 2011; 25: 705-718.
39. Soslow RA, Bissonnette JP, Wilton A, et al., Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007; 31: 979-987.
40. Kobel M, Kalloger SE, Baker PM, et al., Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol 2010; 34: 984-993.
41. Anglesio MS, Carey MS, Kobel M, et al., Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011; 121: 407-415.
42. Alkushi A, Clarke BA, Akbari M, et al., Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007; 20: 1156-1165.
43. Zannoni G, Vellone V, Arena V, et al., Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 2010; 457: 27-34.
44. Crum CP, Lee KR, Genest DR,. Adenocarcinoma, carcinosarcoma and other epithelial tumors of the endometrium. In Diagnostic Gynecologic and Obstetric Pathology (1st edn), Christopher P, Crum KRL, (eds). Saunders/Elsevier: Philadelphia, PA, 2006; 545-610.
45. Amant F, Cadron I, Fuso L, et al., Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005; 98: 274-280.
46. Chiyoda T, Tsuda H, Tanaka H, et al., Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma? Genes Chromosomes Cancer 2012; 51: 229-239.
47. Murray S, Linardou H, Mountzios G, et al., Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res 2010; 686: 68-73.
48. Byron SA, Gartside M, Powell MA, et al., FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE 2012; 7: e30801.
49. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
50. Prahallad A, Sun C, Huang S, et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
51. Corcoran RB, Ebi H, Turke AB, et al., EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-235.
52. Li H, Handsaker B, Wysoker A, et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
53. McKenna A, Hanna M, Banks E, et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
54. Shah SP, Morin RD, Khattra J, et al., Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
55. Shah SP, Roth A, Goya R, et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; DOI: 10.1038/nature10933.
56. Reva B, Antipin Y, Sander C,. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011; 39: e118.